ARTICLE | Company News
Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news
June 3, 2013 7:00 AM UTC
In April, Atopix received a £1.7 million ($2.6 million) award from the U.K. Biomedical Catalyst fund to develop the company's lead compound, OC459, to treat moderate-to-severe atopic dermatitis. The ...